EMERGENT BIOSOLUTIONS INC. (EBS) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 581.80M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 1.12B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | $581.80M | (m) | (m) | $1.12B | (m) |
| 2026-03-31 | (m) | (m) | (m) | $573.60M | (m) | (m) | $1.32B | (m) |
| 2025-12-31 | (m) | (m) | (m) | $572.10M | (m) | (m) | $1.32B | (m) |
| 2025-09-30 | (m) | (m) | (m) | $663.10M | (m) | (m) | $1.46B | (m) |
| 2025-06-30 | (m) | (m) | (m) | $667.80M | (m) | (m) | $1.42B | (m) |
| 2025-03-31 | (m) | (m) | (m) | $665.70M | (m) | (m) | $1.43B | (m) |
| 2024-12-31 | (m) | (m) | $0.00 | $663.70M | (m) | (m) | $1.39B | (m) |
| 2024-09-30 | (m) | (m) | $800.00K | $661.80M | (m) | (m) | $1.48B | (m) |
| 2024-06-30 | (m) | (m) | $415.20M | $447.00M | (m) | (m) | $1.51B | (m) |
| 2024-03-31 | (m) | (m) | $459.20M | $446.70M | (m) | (m) | $1.80B | (m) |
| 2023-12-31 | (m) | (m) | $413.70M | $446.50M | (m) | (m) | $1.82B | (m) |
| 2023-09-30 | (m) | (m) | $413.60M | $448.20M | (m) | (m) | $1.89B | (m) |
| 2023-06-30 | (m) | (m) | $455.20M | $448.00M | (m) | (m) | $2.18B | (m) |
| 2023-03-31 | (m) | (m) | $950.70M | $447.70M | (m) | (m) | $2.95B | (m) |
| 2022-12-31 | (m) | (m) | $957.30M | $448.50M | (m) | (m) | $3.17B | (m) |
| 2022-09-30 | (m) | (m) | $21.20M | $1.03B | (m) | (m) | $2.91B | (m) |
| 2022-06-30 | (m) | (m) | $31.60M | $793.60M | (m) | (m) | $2.74B | (m) |
| 2022-03-31 | (m) | (m) | $31.60M | $801.50M | (m) | (m) | $2.78B | (m) |
| 2021-12-31 | (m) | (m) | $31.60M | $809.40M | (m) | (m) | $2.96B | (m) |
| 2021-09-30 | (m) | (m) | $31.60M | $817.30M | (m) | (m) | $2.87B | (m) |
| 2021-06-30 | (m) | (m) | $28.80M | $825.20M | (m) | (m) | $2.92B | (m) |
| 2021-03-31 | (m) | (m) | $26.00M | $833.10M | (m) | (m) | $2.90B | (m) |
| 2020-12-31 | (m) | (m) | $33.80M | $841.00M | (m) | (m) | $2.88B | (m) |
| 2020-09-30 | (m) | (m) | $30.90M | $848.50M | (m) | (m) | $2.62B | (m) |
| 2020-06-30 | (m) | (m) | $29.10M | $758.10M | (m) | (m) | $2.47B | (m) |
| 2020-03-31 | (m) | (m) | $26.30M | $762.90M | (m) | (m) | $2.28B | (m) |
| 2019-12-31 | (m) | (m) | $12.90M | $798.40M | (m) | (m) | $2.33B | (m) |
| 2019-09-30 | (m) | (m) | $10.10M | $813.30M | (m) | (m) | $2.33B | (m) |
| 2019-06-30 | (m) | (m) | $10.10M | $830.40M | (m) | (m) | $2.32B | (m) |
| 2019-03-31 | (m) | (m) | $10.10M | $732.40M | (m) | (m) | $2.15B | (m) |
| 2018-12-31 | (m) | (m) | $10.10M | $784.50M | (m) | (m) | $2.23B | (m) |
| 2018-09-30 | (m) | (m) | (m) | $13.49M | (m) | (m) | $1.17B | (m) |
| 2018-06-30 | (m) | (m) | (m) | $13.48M | (m) | (m) | $1.14B | (m) |
| 2018-03-31 | (m) | (m) | (m) | $13.47M | (m) | (m) | $1.07B | (m) |
| 2017-12-31 | (m) | (m) | (m) | $13.46M | (m) | (m) | $1.07B | (m) |
| 2017-09-30 | (m) | (m) | (m) | $248.99M | (m) | (m) | $1.02B | (m) |
| 2017-06-30 | (m) | (m) | (m) | $248.69M | (m) | (m) | $970.48M | (m) |
| 2017-03-31 | (m) | (m) | (m) | $248.39M | (m) | (m) | $951.64M | (m) |
| 2016-12-31 | (m) | (m) | (m) | $248.09M | (m) | (m) | $970.11M | (m) |
| 2016-09-30 | (m) | (m) | (m) | $247.79M | (m) | (m) | $932.03M | (m) |
| 2016-06-30 | (m) | (m) | (m) | $247.39M | (m) | (m) | $1.06B | (m) |
| 2016-03-31 | (m) | (m) | (m) | $247.19M | (m) | (m) | $1.04B | (m) |
| 2015-12-31 | (m) | (m) | (m) | $253.00M | (m) | (m) | $1.04B | (m) |
| 2015-09-30 | (m) | (m) | (m) | $253.00M | (m) | (m) | $976.55M | (m) |
| 2015-06-30 | (m) | (m) | (m) | $253.00M | (m) | (m) | $943.32M | (m) |
| 2015-03-31 | (m) | (m) | (m) | $251.00M | (m) | (m) | $917.85M | (m) |
| 2014-12-31 | (m) | (m) | (m) | $251.00M | (m) | (m) | $945.26M | (m) |
| 2014-09-30 | (m) | (m) | (m) | $251.00M | (m) | (m) | $869.29M | (m) |
| 2014-06-30 | (m) | (m) | (m) | $251.00M | (m) | (m) | $837.25M | (m) |
| 2014-03-31 | (m) | (m) | (m) | $251.00M | (m) | (m) | $823.25M | (m) |
| 2013-12-31 | (m) | (m) | $0.00 | $62.00M | (m) | (m) | $626.63M | (m) |
| 2013-09-30 | (m) | (m) | $4.47M | $54.95M | (m) | (m) | $595.46M | (m) |
| 2013-06-30 | (m) | (m) | $4.47M | $56.07M | (m) | (m) | $555.61M | (m) |
| 2013-03-31 | (m) | (m) | $4.47M | $57.19M | (m) | (m) | $538.38M | (m) |
| 2012-12-31 | (m) | (m) | $4.47M | $58.30M | (m) | $141.67M | $564.23M | (m) |
| 2012-09-30 | (m) | (m) | $4.15M | $58.87M | (m) | $197.90M | $540.02M | (m) |
| 2012-06-30 | (m) | (m) | $4.06M | $58.14M | (m) | $161.84M | $527.14M | (m) |
| 2012-03-31 | (m) | (m) | (m) | $57.59M | (m) | $150.43M | $514.69M | (m) |
| 2011-12-31 | (m) | (m) | (m) | $54.09M | (m) | $145.87M | $546.86M | (m) |
| 2011-09-30 | (m) | (m) | $4.92M | $48.87M | (m) | $128.84M | $512.96M | (m) |
| 2011-06-30 | (m) | (m) | $10.23M | $29.07M | (m) | $127.14M | $493.98M | (m) |
| 2010-12-31 | (m) | (m) | $17.19M | $30.24M | (m) | $171.05M | $500.32M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |